All The Claims

1. A cover for a port in a modular system, the cover comprising a dummy module having an outer housing with substantially the same outer dimensions as an operational module that would fit into the port in the modular system, wherein the dummy module includes a printed circuit board within the outer housing, the printed circuit board having substantially the same dimensions as those of a printed circuit board of an operational module.
2. A cover according to claim 1, wherein the printed circuit board includes at least a memory component mounted thereon and electrical conductors on the printed circuit board coupled to the memory component for allowing a controller of the modular system to communicate with the memory component, when the dummy module is in position in the modular system.
3. A cover according to claim 1, wherein the printed circuit board includes resistive termination for containing signals passing thereto from the modular system, when the dummy device is in position in the modular system.
4. A cover according to claim 1, wherein the outer housing comprises an outer housing that could be used to form an operational module.
5. A cover according to claim 1, wherein the outer housing includes an aperture therein, that, in an operational module, would allow an optical connection to be made there through, the aperture of the dummy module being closed off.
6. A cover according to claim 5, wherein the aperture is closed off by means of a plug.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A method for preparing a basement membrane comprising:
culturing cells having an ability to form the basement membrane on a support structure with a sugar-chain coat,
wherein the sugar-chain coat has a \u03b2-D-glucopyranosyl non-reducing end or a 2-acetoamide-2-deoxy-\u03b2-D-glucopyranosyl non-reducing end, and
wherein the culturing is under conditions such that the cells are in contact with the support structure with the sugar-chain coat, and the \u03b2-D-glucopyranosyl non-reducing end or 2-acetoamide-2-deoxy-\u03b2-D-glucopyranosyl non-reducing end can localize a receptor on the cells to thereby accumulate basement membrane components onto a basal surface of the cells and form the basement membrane.
2. The method of claim 1 further comprising preparing the support structure with the sugar-chain coat comprising coating the support structure with the sugar-chain coat.
3. The method of claim 1, wherein the support structure is a fibrous collagen.
4. The method of claim 1, wherein the support structure is coated with a polymer having a sugar chain comprising PV-GlcNAc, PV-CA or PV-Lam.
5. The method of claim 1, wherein the support structure has opposing surfaces and is coated by the sugar chain on both of its opposing surfaces.
6. The method of claim 5, wherein the cells having the ability to form the basement membrane are cultured on both of the opposing surfaces of the support structure.
7. The method of claim 1, wherein the cells having an ability to form a basement membrane comprise epithelial cells, endothelial cells or mesenchymal cells.
8. The method of claim 1, wherein the cells having an ability to form a basement membrane are co-cultured with fibroblasts.
9. The method of claim 1, wherein the cells having an ability to form a basement membrane are cultured in the presence of one or more types of basement membrane components comprising laminin, type IV collagen, heparan sulfate proteoglycan (HSPG), or entactin.
10. The method of claim 1, wherein the cells having an ability to form a basement membrane are cultured in the presence of TGF-\u03b2 (transforming growth factor-\u03b2).
11. The method of claim 1, wherein the cells having an ability to form a basement membrane are transfected with one or more genes encoding one or more basement membrane components in order to hyper-express one or more basement membrane components.
12. The method of claim 1, wherein a part of the sugar chain coat is replaced by a basement membrane component.

1. A light emitting device comprising:
a substrate having a mounting surface; and
one hundred or more light emitting elements placed on the mounting surface of the substrate, the light emitting elements each having a light emitting area of 2,500\u03c0 \u03bcm2 or less,
at least one of the light emitting elements being in shape of a bar,
the at least one light emitting element in shape of a bar having a cylindrical light emitting surface that concentrically surrounds a bar-like core,
no pn junctions, which are perpendicular to an axis direction of the bar, existing in the middle of the bar, and
an area of the mounting surface of the substrate being equal to or larger than four times as large as a sum total of the light emitting areas of the light emitting elements.
2. The light emitting device as claimed in claim 1, wherein
the bar-like core of the at least one light emitting element is an n-type semiconductor core, and
the at least one light emitting element has a cylindrical p-type semiconductor layer covering an outer peripheral surface of the n-type semiconductor core.
3. The light emitting device as claimed in claim 1, wherein the light emitting area of each of the light emitting elements is not larger than 625\u03c0 \u03bcm2.
4. The light emitting device as claimed in claim 3, wherein
difference between a center temperature of the light emitting surface and an end part temperature of the light emitting surface is around zero during light emitting operations of the light emitting elements.
5. The light emitting device as claimed in claim 1, wherein
the light emitting elements are placed on the mounting surface of the substrate while being dispersed uniformly in general.
6. An illuminating device comprising the light emitting device as claimed in claim 1.
7. A backlight comprising the light emitting device as claimed in claim 1.
8. A light emitting device comprising:
a substrate having a mounting surface; and
one hundred or more light emitting elements placed on the mounting surface of the substrate, the light emitting elements each having a light emitting area of 2,500\u03c0 \u03bcm 2 or less,
an area of the mounting surface of the substrate being equal to or larger than four times as large as a sum total of the light emitting areas of the light emitting elements.
9. The light emitting device as claimed in claim 8, wherein the light emitting area of each of the light emitting elements is not larger than 625\u03c0 \u03bcm 2.
10. The light emitting device as claimed in claim 9, wherein
difference between a center temperature of the light emitting surface and an end part temperature of the light emitting surface is around zero during light emitting operations of the light emitting elements are emitting light.
11. The light emitting device as claimed in claim 8, wherein the light emitting elements are dispersed uniformly in general on the mounting surface of the substrate.
12. The light emitting device as claimed in claim 8, wherein each of the light emitting elements has a flat light emitting surface or a cylindrical light emitting surface.
13. An illuminating device comprising the light emitting device as claimed in claim 8.
14. A backlight comprising the light emitting device as claimed in claim 8.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (I)
or a pharmaceutically acceptable salt thereof; wherein
X is a linker group selected from \u2014CR4\u2550CR5\u2014, \u2014CR4\u2550CR5CR6R7\u2014, \u2014CR6R7CR5\u2550CR4\u2014, \u2014C\u2261C\u2014, \u2014C\u2261CCR6R7\u2014, \u2014NR4CR6R7\u2014, \u2014OCR6R7\u2014, \u2014SCR6R7\u2014, \u2014S(O)CR6R7\u2014, \u2014S(O)2CR6R7\u2014, \u2014C(O)NR4CR6R7\u2014, \u2014NR4C(O)CR6R7\u2014, \u2014NR4C(O)NR5CR6R7\u2014, \u2014NR4S(O)2CR6R7\u2014, \u2014S(O)2NR4CR6R7\u2014, \u2014C(O)NR4\u2014, \u2014NR4C(O)\u2014, \u2014NR4C(O)NR5\u2014, \u2014S(O)2NR4\u2014 and \u2014NR4S(O)2\u2014;
1Y and Y2 are independently N or CR8 provided that one of 1Y and Y2 is N and the other is CR8;
R1 is a group selected from C1-6alkyl, C2-6alkenyl, C2-6alkynyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl, which group is optionally substituted by one or more substituent group selected from halo, cyano, nitro, R9, \u2014OR9, \u2014SR9, \u2014SO2R9, \u2014COR9, \u2014CO2R9, \u2014CONR9R10, \u2014NR9R10, \u2014NR9COR10, \u2014NR9CO2R10, \u2014NR9CONR10R15, \u2014NR9COCONR10R15 and \u2014NR9SO2R10;
R2 is a group selected from C1 alkyl, carbocyclyl and heterocyclyl which group is optionally substituted by one or more substituent group independently selected from halo, cyano, nitro, \u2014R11, \u2014OR11, \u2014SR11, \u2014SOR11, \u2014SO2R11, \u2014COR11, \u2014CO2R11, \u2014CONR11R12, \u2014NR11R12, and \u2014NR11COCONR12R16;
R3 is selected from halo, cyano, nitro, \u2014R13, \u2014OR13, \u2014SR13, \u2014SOR13, \u2014SO2R13, \u2014COR13, \u2014CO2R13, \u2014CONR13R14, \u2014NR13R14, \u2014NR13COR14, \u2014NR13CO2R14 and \u2014NR13SO2R14;
R4 and R5 are independently hydrogen or C1-6alkyl;
or R1 and R4 together with the atom or atoms to which they are attached form a 4- to 10-membered carbocyclic or heterocyclic ring wherein 1, 2 or 3 ring carbon atoms is optionally replaced with N, O or S and which ring is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, oxo, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6allcoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R6 and R7 are independently selected from hydrogen, halo, cyano, nitro and C1-6alkyl;
R8 is selected from hydrogen, halo, cyano and C1-6alkyl;
R9 and R10 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R11 and R12 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl;
R13, R14, R15 and R16 are independently hydrogen or a group selected from C1-6alkyl, carbocyclyl, carbocyclylC1-6alkyl, heterocyclyl and heterocyclylC1-6alkyl which group is optionally substituted by one or more substituent groups selected from halo, cyano, nitro, hydroxy, C1-6alkyl, C1-6alkoxy, haloC1-6alkyl, haloC1-6alkoxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkyl, C1-6alkoxyC1-6alkoxy, amino, C1-6alkylamino, bis(C1-6alkyl)amino, aminoC1-6alkyl, (C1-6alkyl)aminoC1-6alkyl, bis(C1-6alkyl)aminoC1-6alkyl, cyanoC1-6alkyl, C1-6alkylsulfonyl, C1-6alkylsulfonylamino, C1-6alkylsulfonyl(C1-6alkyl)amino, sulfamoyl, C1-6alkylsulfamoyl, bis(C1-6alkyl)sulfamoyl, C1-6alkanoylamino, C1-6alkanoyl(C1-6alkyl)amino, carbamoyl, C1-6alkylcarbamoyl and bis(C1-6alkyl)carbamoyl.
2. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein 1Y is CH and Y2 is N.
3. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein X is \u2014S(O)2CR6R7\u2014 or \u2014C(O)NHR4\u2014.
4. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 3 wherein X is \u2014S(O)2CH2\u2014, \u2014S(O)2CH(CH3)\u2014, \u2014S(O)2C(CH3)2\u2014 or \u2014C(O)NH\u2014.
5. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R1 is a group selected from methyl, ethyl, isopropyl, sec-butyl, isobutyl, phenyl, 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl and 4-(anilinocarbonyl)aminophenyl.
6. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 5 wherein \u2014XR1 is a group selected from \u2014CH2SO2\u2014R1 and \u2014C(CH3)2SO2\u2014R1 wherein R1 is methyl, ethyl, isopropyl, sec-butyl, isobutyl or phenyl; or \u2014XR1 is \u2014NHCO\u2014R1 wherein R1 is 2-methoxyphenyl, 3-methoxyphenyl, 3-fluoro-4-methoxyphenyl, 4-methoxy-3-trifluoromethylphenyl, 2-methoxypyridin-5-yl, 2-methoxypyridin-4-yl, 2-methoxypyridin-4-yl, 2-acetamidopyridin-5-yl, 2-acetamidopyridin-4-yl or 4-(anilinocarbonyl)aminophenyl.
7. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R2 is selected from morpholinyl, piperidinyl, phenyl, naphthyl, pyrrolyl, imidazolyl, pyrazolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyridazinyl, azaindolyl, indolyl, quinolinyl, benzimidazolyl, benzofuranyl, dibenzofuranyl, benzothienyl which group is optionally substituted by one or more substituent group independently selected from halo, methyl, methoxy, hydroxymethyl, cyanomethyl, phenoxy, pyrrolidinyl, \u2014CONH2, \u2014CONHCH3 and \u2014CON(CH3)2.
8. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 wherein R2 is (pyrazol-3yl)amino, hydroxypiperidinyl, indol-4-yl, indol-5-yl, indol-6-yl, azaindolyl, benzimidazol-5-yl, 3-(pyrazol-4-yl)phenyl, 4-(pyrazol-4-yl)phenyl, 2-aminocarbonylindol-5-yl, 3-aminocarbonylindol-5-yl, 2-aminocarbonylindol-6-yl, 3-aminocarbonylindol-6-yl, morpholinyl, 2-(pyrazol-4-yl)thiazol-5yl or methylmorpholinyl.
9. A compound of formula (I), or a pharmaceutically acceptable salt thereof, according to claim 1 selected from any one of
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-methoxy-benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-methoxy-3-(trifluoromethyl)benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-3-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-methoxy-3-(trifluoromethyl)benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-3-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-6-methoxy-pyridine-3-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-2-methoxy-pyridine-4-carboxamide,
6-Acetamido-N-2,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-ylpyridine-3-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-2-methoxy-benzamide,
2-Acetamido-N-2,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-ylpyridine-4-carboxamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-3-fluoro-4-methoxy-benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-2-methoxy-pyridine-4-carboxamide,
6-Acetamido-N-4,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-ylpyridine-3-carboxamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-2-methoxy-benzamide,
2-Acetamido-N-4,6-bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-ylpyridine-4-carboxamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-3-fluoro-4-methoxy-benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-(phenylcarbamoylamino)benzamide,
N-4,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-4-(phenylcarbamoylamino)benzamide,
N-2,6-Bis(3S)-3-methylmorpholin-4-ylpyrimidin-4-yl-4-methoxy-benzamide,
2-(2R,6S)-2,6-Dimethylmorpholin-4-yl-4-(3S)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidine,
1-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-ylpiperidin-3-ol,
4-(3S)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-morpholin-4-yl-pyrimidine,
3-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(3R)-3-methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(Butan-2-ylsulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(butan-2-ylsulfinylmethyl)-6-(3R)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(3R)-3-methylmorpholin-4-yl-6-(propan-2-ylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
5-4-(ethylsulfonylmethyl)-6-(3R)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-N-(1H-pyrazol-3-yl)pyrimidin-2-amine,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-4-(1H-pyrazol-4-yl)phenylpyrimidine,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-3-(1H-pyrazol-4-yl)phenylpyrimidine,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-3-carboxamide,
4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)-2-2-(1H-pyrazol-4-yl)-1,3-thiazol-5-ylpyrimidine,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-3-carboxamide,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-2-carboxamide,
6-4-(3S)-3-Methylmorpholin-4-yl-6-(methylsulfonylmethyl)pyrimidin-2-yl-1H-indole-2-carboxamide,
5-4-(3S)-3-Methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-benzoimidazole,
3-4-(3S)-3-Methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
5-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
4-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
6-4-(3S)-3-methylmorpholin-4-yl-6-(2-methylsulfonylpropan-2-yl)pyrimidin-2-yl-1H-indole,
4-4-(Benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
5-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole,
3-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-5,7-diazabicyclo4.3.0nona-1,3,5,8-tetraene,
6-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-indole, or
5-4-(benzenesulfonylmethyl)-6-(3S)-3-methylmorpholin-4-ylpyrimidin-2-yl-1H-benzoimidazole, or a pharmaceutically acceptable salt thereof.
10-13. (canceled)
14. A method for producing an anti-proliferative effect in a warm-blooded animal in need of such treatment which comprises administering to said animal an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1.
15. A method for treating cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases in a warm blooded animal that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1.
16. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.
17. (canceled)
18. A method for treating cancer, inflammatory diseases, obstructive airways diseases, immune diseases or cardiovascular diseases in a warm blooded animal that is in need of such treatment which comprises administering an effective amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 9.
19. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 9, or a pharmaceutically acceptable salt thereof, in association with a pharmaceutically acceptable diluent or carrier.